Why it matters
The deaths and workforce cuts affect the company and people involved in its trials. The supplied report does not establish whether the trial program has been paused or what the events mean for other treatments or patients.
RESEARCH & TREATMENTS • UNITED STATES
California biotech lays off most staff after two cell-therapy trial deaths
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
Artiva has laid off nearly all its staff after two deaths among patients in its cell-therapy trials, The Epoch Times reports. Artiva said one death was likely due to neurotoxicity; the cause of the other remains undetermined.
HOW THIS BRIEF WAS MADE 1 outlet: 1 national. Automated sourcing and summaries by the BLUF engine. Corrections